all the information, none of the junk | biotech • healthcare • life sciences

Zipcar Files for $75M IPO, Tetraphase Gets $45M, Covidien Acquires ev3 for $2.6B, & More Boston-Area Deals News

(Page 2 of 2)

roll Fermentas into its analytical technologies unit.

—Watertown, MA-based antibiotic developer Tetraphase Pharmaceuticals pulled in a $45 million Series C round, led by new investor Excel Venture Management. Tetraphase also received support from its existing backers CMEA Ventures, Fidelity Biosciences, Flagship Ventures, Mediphase Venture Partners, and Skyline Ventures.The company has now raised a total of $80 million.

—SynapDx, a Waltham startup working on technology for early stage detection of autism, said it has pulled in a $9 million Series A round, thanks to Bain Capital, General Catalyst Partners, and North Bridge Venture Partners.

—Cambridge, MA-based car sharing service Zipcar filed for a $75 million initial public offering. Earlier this spring, the company acquired Streetcar, a U.K. service with a similar business model, and borrowed $70 million through a one-year credit facility to use for expanding its U.S. fleet. Zipcar boasts more than 400,000 members, and covers 13 cities.

—Boston-based Excel Venture Management and angel investors have pumped $2.3 million in seed funding to Snaptic, a San Francisco maker of the 3Banana note-taking app for iPhone and Android. Snaptic CEO Steve Brown told VentureWire that 3Banana’s ability to help users track fitness, diet, and health information caught the eye of Excel, an investment firm focused on healthcare companies.

Covidien, a healthcare products company with headquarters in Mansfield, MA, announced it will buy Plymouth, MN-based medical devices firm ev3 (NASDAQ: EVVV), for $2.6 billion, or $22.50 per share in cash. Covidien (NYSE: COV) said it expects the deal to close by July 31.

Single PageCurrently on Page: 1 2 previous page